Kiniksa Pharmaceuticals International (KNSA) Income towards Parent Company: 2021-2025
Historic Income towards Parent Company for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $18.4 million.
- Kiniksa Pharmaceuticals International's Income towards Parent Company rose 245.24% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 142.99%. This contributed to the annual value of -$43.2 million for FY2024, which is 28.48% up from last year.
- Latest data reveals that Kiniksa Pharmaceuticals International reported Income towards Parent Company of $18.4 million as of Q3 2025, which was up 3.38% from $17.8 million recorded in Q2 2025.
- Kiniksa Pharmaceuticals International's 5-year Income towards Parent Company high stood at $224.1 million for Q3 2022, and its period low was -$49.5 million during Q1 2021.
- In the last 3 years, Kiniksa Pharmaceuticals International's Income towards Parent Company had a median value of -$8.9 million in 2024 and averaged -$5.3 million.
- In the last 5 years, Kiniksa Pharmaceuticals International's Income towards Parent Company soared by 833.67% in 2022 and then plummeted by 155.63% in 2023.
- Over the past 5 years, Kiniksa Pharmaceuticals International's Income towards Parent Company (Quarterly) stood at -$44.1 million in 2021, then soared by 300.84% to $88.5 million in 2022, then plummeted by 155.63% to -$49.2 million in 2023, then spiked by 81.95% to -$8.9 million in 2024, then spiked by 245.24% to $18.4 million in 2025.
- Its Income towards Parent Company stands at $18.4 million for Q3 2025, versus $17.8 million for Q2 2025 and $8.5 million for Q1 2025.